Rilpivirine (Edurant, TMC278)

Overview | News & Research

Overview

Prescribing Information for Edurant (Rilpivirine) Tablets (PDF) (December 2012)
From Janssen Pharmaceuticals, Inc.
DHHS Adult and Adolescent Antiretroviral Treatment Guidelines Panel Releases Supplemental Information Regarding the Role of Rilpivirine as Initial Therapy (August 16, 2011)
To read PDF, click here.
From AIDSinfo
Edurant (Rilpivirine): The HIV Treatment Dating Game Just Got More Interesting (May 26, 2011)
An interview with Cal Cohen, M.D.
From TheBody.com

News & Research

ARV Pipeline: Long-Acting Formulations of Rilpivirine, GSK-744 and Nanoformulations (March/April 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Labeling Updates for Edurant (Rilpivirine) (January 3, 2013)
From U.S. Food and Drug Administration
Switching to Rilpivirine/Tenofovir/FTC Fixed-Dose Combination From Boosted-PI Regimen: SPIRIT Study Draws the Line at 24 Weeks (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Early Data for Rilpivirine Long-Acting Formulation Supports Further Investigation for PrEP (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Studies on Pipeline Antiretrovirals Reveal New Data on Possible Drug Interactions (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Once-a-Month HIV Drug Maintains Good Levels for Prevention; Few Side-Effects So Far (March 7, 2012)
From aidsmap.com
Similar Efficacy and a Few Gender-Related Differences in Side Effects With Rilpivirine Versus Efavirenz at 96 Weeks (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Conference Update From IAS 2011: Medication News (September/October 2011)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Large Sample Analysis Confirms Impact of Known Rilpivirine Mutations (September 21, 2011)
From National AIDS Treatment Advocacy Project
Better 1-Month Safety With Rilpivirine Than Efavirenz in Treatment-Naive (September 21, 2011)
From National AIDS Treatment Advocacy Project

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	CROI 2013: Women's Issues in HIV Research (Video)
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
	HIV Opportunistic Infection Guidelines Updated

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.